Variant
ABL1 P-Loop Mutation
CI-VAR-00003260Explore in graph →CIViC 2375
Curated evidence
Evidence by cancer (4 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26040495
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Acute Lymphoblastic Leukemia1 | ||||||||
| ABL1 TKD Mutation OR ABL1 P-Loop Mutation OR ABL1 Non-P-Loop Mutation | Bosutinib | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID11339In this phase 1/2, open‐label, two‐part study, advanced leukemia patients with prior treatment failure (accelerated‐phase [AP, n = 79] chronic myeloid leukemia [CML], blast‐phase [BP, n = 64] CML, acu… (full text at CIViC) PMID 26040495 · Gambacorti-Passerini et al., 2015 · Open in CIViC | civic |
| Chronic Myeloid Leukemia, BCR-ABL1 Positive3 | ||||||||
| ABL1 P-Loop Mutation | Bosutinib | Predictive | B | Does Not Support Resistance | 3 | accepted | EID6336In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Among 115 patients with mutational analysi… | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available